Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share
After 12 Months Of US Competition, Uptake Remains Low For Adalimumab Biosimilars
• By David Wallace
Biosimilars have captured a small market share, at lower prices • Source: Shutterstock 
